Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cerilliant
Medtronic
Covington
QuintilesIMS
Citi
US Department of Justice
Merck
UBS

Generated: November 18, 2018

DrugPatentWatch Database Preview

Glenmark Generics Company Profile

« Back to Dashboard

What is the competitive landscape for GLENMARK GENERICS, and what generic and branded alternatives to GLENMARK GENERICS drugs are available?

GLENMARK GENERICS has sixty-eight approved drugs.

There are three tentative approvals on GLENMARK GENERICS drugs.

Summary for Glenmark Generics
US Patents:0
Tradenames:59
Ingredients:54
NDAs:68
Patent Litigation for Glenmark Generics: See patent lawsuits for Glenmark Generics

Drugs and US Patents for Glenmark Generics

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Generics PRAVASTATIN SODIUM pravastatin sodium TABLET;ORAL 077987-002 May 11, 2007 AB RX No No ➤ Sign Up ➤ Sign Up
Glenmark Generics ZOLMITRIPTAN zolmitriptan TABLET;ORAL 201779-002 May 14, 2013 AB RX No No ➤ Sign Up ➤ Sign Up
Glenmark Generics IMIQUIMOD imiquimod CREAM;TOPICAL 201994-001 Mar 6, 2012 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GLENMARK GENERICS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Boehringer Ingelheim
Queensland Health
Cerilliant
US Army
AstraZeneca
McKesson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.